

PuriCore Launches Vashe Wound Therapy for Instillation Applications

New Wound Care Product for Use in Ultrasonic Debridement and Negative-Pressure Wound Therapy

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, November 17, 2011 — [PuriCore](#) (LSE: PURI), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announced the launch of its new Vashe Wound Therapy for Instillation Applications, a safe, natural, and effective solution for adjunctive therapies for wound care including ultrasonic debridement and negative-pressure wound therapy.

Vashe Wound Therapy is a solution of hypochlorous acid, the same naturally occurring chemical used by the human body to defend against invading pathogens, and is used in wound care clinics and hospitals throughout the country for successful chronic and acute wound treatments. Vashe Wound Therapy for Instillation Applications is available in various pack sizes of 125-ml, 250-ml, and 500-ml ml bottles and incorporates a hanger system and septum cap assembly that work in conjunction with a vented infusion set for controlled flow of the wound care solution.

Vashe Wound Therapy is intended for moistening, irrigating, cleaning, and debriding acute and chronic wounds including stage I through IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first and second degree burns, abrasions, and minor irritations of the skin. The hypochlorous acid in Vashe Wound Therapy acts as a preservative to rapidly kill 99.999% of *MRSA*, *VRE*, *Acinetobacter baumannii*, *E. Coli*, and other dangerous pathogens in solution in just 15 seconds in laboratory testing with no known microbial resistance. Vashe Wound Therapy with preservative passes the USP<51> Antimicrobial Effectiveness Test, demonstrating rapid effective activity in solution against a broad spectrum of gram-positive, gram-negative, and yeast species. A full list of Antimicrobial Effectiveness Test data is available from PuriCore.

Vashe Wound Therapy is demonstrated to be extremely safe, gentle, and hypoallergenic. It is tissue-friendly and can be applied directly to wounds even around eyes, mouth, and nose. Vashe has also been rigorously safety tested: it is non-cytotoxic, non-irritating, non-sensitizing, non-mutagenic, and indicates no oral toxicity. It also shows no antibiotic resistance and has no clinical contraindications for prescription use.

“We have used Vashe Wound Therapy in our clinic for several years and have realized excellent clinical outcomes on thousands of patients with a wide variety of very difficult chronic and acute wounds,” said Jeffrey A. Niezgoda, MD, FACHM, MAPWCA, Medical Director of The Center for Comprehensive Wound Care & Hyperbaric Oxygen Therapy, St. Luke’s Medical Center in Milwaukee, WI. “Vashe has essentially replaced saline in our wound care protocols. As ultrasonic debridement and negative-pressure wound therapy are integral to our management strategies, we welcome the new offering of Vashe Wound Therapy for Instillation Applications.”

“Every year, more and more Americans visit wound care centers as the prevalence of difficult-to-treat wounds increases, and we are pleased to now be able to offer Vashe Wound Therapy for Instillation Applications, addressing these important adjunctive wound care therapies,” said Greg Bosch, CEO of PuriCore. “Clinicians across the country depend on our Vashe products, offering the most robust concentration of hypochlorous acid commercially available in a wound cleanser.”

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore’s patented, proprietary technology mimics the human body’s production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company’s products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of *C.difficile*, *E.coli*, HIV, Human and Animal Influenza (including H1N1 and H5N1), *Legionella*, *MRSA*, *M.tuberculosis*, Norovirus, and *Salmonella*. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Contacts:

Sage Strategic Marketing
Jennifer Guinan
610.410.8111

PuriCore
Greg Bosch, CEO
484.321.2700